Ozempic and Mounjaro may have a surprising effect on your brain

Researchers are investigating whether GLP-1 medications like Ozempic and Mounjaro, primarily used for diabetes and weight loss, offer cognitive benefits. While some observational data suggests a link to lower dementia risk, clinical trials have yet to prove they slow Alzheimer's progression.
Why it matters
Understanding the secondary effects of widely used drugs is critical for public health, especially as researchers look for new ways to combat cognitive decline.
Popular medications used to treat obesity and type 2 diabetes, including semaglutide and tirzepatide, may have effects that extend beyond weight loss and blood sugar control. These drugs also influence biological processes involved in brain function, raising questions about whether they could help preserve memory and thinking abilities.
To examine this possibility, researchers from the University of Gothenburg and the University of Copenhagen reviewed the existing scientific evidence at the invitation of the journal Science .
Studies involving animals suggest that GLP-1 medications can influence learning and memory. However, research involving humans has produced less consistent findings. Analyses of patient health records have found an association between GLP-1 treatment and a reduced risk of dementia among people with type 2 diabetes. These observational findings are encouraging, but they cannot determine whether the medications themselves are responsible for the lower risk.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in